$VASO
VASO Corp Stock $vaso

$vaso Overview Financials Valuation SEC Filings Company Website

2021 Form 10-K Financial Statement

#000165495422004333 Filed on March 31, 2022

Income Statement

Concept	2021	2020 Q4	2020
Revenue	$75.58M	$18.69M	$69.85M
YoY Change	8.2%	-21.2%	-7.5%
Cost Of Revenue	$32.45M	$7.615M	$31.28M
YoY Change	3.73%	-19.23%	-5.45%
Gross Profit	$43.13M	$11.08M	$38.57M
YoY Change	11.83%	-22.51%	-9.1%
Gross Profit Margin	57.07%	59.26%	55.22%
Selling, General & Admin	$38.59M	$9.568M	$37.05M
YoY Change	4.15%	-14.14%	-9.69%
% of Gross Profit	89.47%	86.38%	96.07%
Research & Development	$1.721M	$210.0K	$745.0K
YoY Change	131.01%	11.11%	-8.36%
% of Gross Profit	3.99%	1.9%	1.93%
Depreciation & Amortization	$3.840M	$601.0K	$2.462M
YoY Change	55.97%	-8.52%	-8.17%
% of Gross Profit	8.9%	5.43%	6.38%
Operating Expenses	$40.31M	$9.774M	$37.80M
YoY Change	6.65%	-13.76%	-9.66%
Operating Profit	$2.819M	$1.302M	$772.0K
YoY Change	265.16%	-56.01%	30.63%
Interest Expense	-$214.0K	-$30.00K	-$415.0K
YoY Change	-48.43%	-87.65%	-51.86%
% of Operating Profit	-7.59%	-2.3%	-53.76%
Other Income/Expense, Net	$3.432M		-$415.0K
YoY Change	-926.99%
Pretax Income	$6.251M	$1.272M	$357.0K
YoY Change	1650.98%	-53.18%	-231.73%
Income Tax	-$151.0K	$96.00K	$1.000K
% Of Pretax Income	-2.42%	7.55%	0.28%
Net Earnings	$6.100M	$1.176M	$358.0K
YoY Change	1603.91%	-55.71%	-193.72%
Net Earnings / Revenue	8.07%	6.29%	0.51%
Basic Earnings Per Share	$0.04		$0.00
Diluted Earnings Per Share	$35.10K	$6.699K	$2.095K
COMMON SHARES
Basic Shares Outstanding	171.7K shares		169.9K shares
Diluted Shares Outstanding	173.8K shares		170.8K shares

Balance Sheet

Concept	2021	2020 Q4	2020
SHORT-TERM ASSETS
Cash & Short-Term Investments	$6.654M	$7.585M	$7.585M
YoY Change	-12.27%	257.11%	257.11%
Cash & Equivalents	$6.025M	$6.819M	$6.819M
Short-Term Investments	$629.0K	$766.0K	$766.0K
Other Short-Term Assets	$4.543M	$3.505M	$3.505M
YoY Change	29.61%	-15.01%	-15.01%
Inventory	$1.147M	$1.384M	$1.384M
Prepaid Expenses
Receivables	$15.39M	$13.96M	$9.776M
Other Receivables	$66.00K	$18.00K	$18.00K
Total Short-Term Assets	$27.80M	$22.27M	$22.27M
YoY Change	24.86%	-7.44%	-7.44%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.087M	$3.885M	$4.894M
YoY Change	-36.92%	-33.29%	-15.97%
Goodwill		$15.69M
YoY Change		-9.17%
Intangibles
YoY Change
Long-Term Investments	$1.043M	$1.116M	$1.116M
YoY Change	-6.54%
Other Assets	$2.665M	$2.190M	$2.461M
YoY Change	8.29%	-24.72%	-15.4%
Total Long-Term Assets	$24.56M	$28.11M	$28.11M
YoY Change	-12.63%	-7.25%	-7.25%
TOTAL ASSETS
Total Short-Term Assets	$27.80M	$22.27M	$22.27M
Total Long-Term Assets	$24.56M	$28.11M	$28.11M
Total Assets	$52.36M	$50.38M	$50.38M
YoY Change	3.94%	-7.34%	-7.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.797M	$6.285M	$6.285M
YoY Change	-55.5%	1.72%	1.72%
Accrued Expenses	$8.182M	$7.502M	$7.502M
YoY Change	9.06%	-15.54%	-15.54%
Deferred Revenue		$11.52M
YoY Change
Short-Term Debt	$3.000K	$236.0K	$236.0K
YoY Change	-98.73%	1142.11%	1142.11%
Long-Term Debt Due	$230.0K	$6.160M	$6.160M
YoY Change	-96.27%	50.13%	50.13%
Total Short-Term Liabilities	$31.00M	$31.70M	$31.70M
YoY Change	-2.21%	0.54%	0.54%
LONG-TERM LIABILITIES
Long-Term Debt	$241.0K	$6.025M	$6.025M
YoY Change	-96.0%	-29.76%	-29.76%
Other Long-Term Liabilities	$9.810M	$910.0K	$7.567M
YoY Change	29.64%	-89.1%	-9.32%
Total Long-Term Liabilities	$10.05M	$13.59M	$13.59M
YoY Change	-26.05%	-19.68%	-19.68%
TOTAL LIABILITIES
Total Short-Term Liabilities	$31.00M	$31.70M	$31.70M
Total Long-Term Liabilities	$10.05M	$13.59M	$13.59M
Total Liabilities	$41.05M	$45.29M	$45.29M
YoY Change	-9.36%	-6.76%	-6.76%
SHAREHOLDERS EQUITY
Retained Earnings		-$57.00M
YoY Change
Common Stock		$185.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)		$2.000M
YoY Change
Treasury Stock Shares		10.31M shares
Shareholders Equity	$11.31M	$5.085M	$5.085M
YoY Change
Total Liabilities & Shareholders Equity	$52.36M	$50.38M	$50.38M
YoY Change	3.94%	-7.34%	-7.34%

Cashflow Statement

Concept	2021	2020 Q4	2020
OPERATING ACTIVITIES
Net Income	$6.100M	$1.176M	$358.0K
YoY Change	1603.91%	-55.71%	-193.72%
Depreciation, Depletion And Amortization	$3.840M	$601.0K	$2.462M
YoY Change	55.97%	-8.52%	-8.17%
Cash From Operating Activities	$7.815M	$1.200M	$5.934M
YoY Change	31.7%	67.36%	-545.16%
INVESTING ACTIVITIES
Capital Expenditures	$415.0K	-$365.0K	$1.000M
YoY Change	-58.5%	15.51%	-182.99%
Acquisitions
YoY Change
Other Investing Activities	$155.0K	-$725.0K	$425.0K
YoY Change	-63.53%		1831.82%
Cash From Investing Activities	-$260.0K	-$1.090M	-$575.0K
YoY Change	-54.78%	244.94%	-51.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$43.13M		$38.57M
YoY Change	11.83%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$8.329M	-88.00K	-$553.0K
YoY Change	1406.15%	-124.31%	-128.97%
NET CHANGE
Cash From Operating Activities	$7.815M	1.200M	$5.934M
Cash From Investing Activities	-$260.0K	-1.090M	-$575.0K
Cash From Financing Activities	-$8.329M	-88.00K	-$553.0K
Net Change In Cash	-$794.0K	22.00K	$4.695M
YoY Change	-116.91%	-97.12%	-873.48%
FREE CASH FLOW
Cash From Operating Activities	$7.815M	$1.200M	$5.934M
Capital Expenditures	$415.0K	-$365.0K	$1.000M
Free Cash Flow	$7.400M	$1.565M	$4.934M
YoY Change	49.98%	51.5%	-3954.69%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2190000	USD
CY2021	dei	Auditor Location AuditorLocation	Houston, Texas
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6025000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6819000	USD
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	629000	USD
CY2020Q4	us-gaap	Short Term Investments ShortTermInvestments	766000	USD
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	5804000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	4208000	USD
CY2021Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	15393000	USD
CY2020Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	9776000	USD
CY2021Q4	us-gaap	Accounts Receivable Related Parties AccountsReceivableRelatedParties	66000	USD
CY2020Q4	us-gaap	Accounts Receivable Related Parties AccountsReceivableRelatedParties	18000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	1147000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	1384000	USD
CY2021Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	3549000	USD
CY2020Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	2354000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	994000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1151000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	27803000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	22268000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10512000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8833000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2172000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3885000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	915000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1009000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	15722000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	15688000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2041000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3949000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2446000	USD
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments	1043000	USD
CY2020Q4	us-gaap	Long Term Investments LongTermInvestments	1116000	USD
CY2021Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	219000	USD
CY2020Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	271000	USD
CY2021Q4	us-gaap	Assets Assets	52361000	USD
CY2020Q4	us-gaap	Assets Assets	50376000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2797000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6285000	USD
CY2021Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	2705000	USD
CY2020Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	1187000	USD
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	7489000	USD
CY2020Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	5154000	USD
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	222000	USD
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	190000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	562000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	540000	USD
CY2021Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	719000	USD
CY2020Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	621000	USD
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	16495000	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	38571000	USD
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	218000	USD
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	38593000	USD
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	37054000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1721000	USD
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	32446000	USD
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	31279000	USD
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	43133000	USD
CY2020Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	5779000	USD
CY2020Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	11516000	USD
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	8000	USD
CY2020Q4	us-gaap	Notes Payable Current NotesPayableCurrent	5970000	USD
CY2021Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	3000	USD
CY2020Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	236000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	31000000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	31699000	USD
CY2021Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	23000	USD
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	246000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	352000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	469000	USD
CY2021Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	8470000	USD
CY2020Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	6188000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	988000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	910000	USD
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	10051000	USD
CY2020Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	13592000	USD
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	185435965	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	185244299	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	175127878	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	174936212	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	185000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	185000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	63917000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	63886000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-50902000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-57002000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	110000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	16000	USD
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	10308087	shares
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	2000000	USD
CY2020Q4	us-gaap	Treasury Stock Value TreasuryStockValue	2000000	USD
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	11310000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5085000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	52361000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	50376000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	75579000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	69850000	USD
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	385000	USD
CY2020	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	745000	USD
CY2021	us-gaap	Operating Expenses OperatingExpenses	40314000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	37799000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	2819000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	772000	USD
CY2021	us-gaap	Interest And Debt Expense InterestAndDebtExpense	312000	USD
CY2020	us-gaap	Interest And Debt Expense InterestAndDebtExpense	701000	USD
CY2021	vaso	Interest And Other Income Expense InterestAndOtherIncomeExpense	98000	USD
CY2020	vaso	Interest And Other Income Expense InterestAndOtherIncomeExpense	176000	USD
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	3646000	USD
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2021	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	USD
CY2020	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	110000	USD
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3432000	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-415000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	6251000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	357000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-151000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1000	USD
CY2021	us-gaap	Net Investment Income NetInvestmentIncome	6100000	USD
CY2020	us-gaap	Net Investment Income NetInvestmentIncome	358000	USD
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	94000	USD
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	142000	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	6194000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	500000	USD
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.04
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	171688	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	169932	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	173771	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	170846	shares
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	4314000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	88000	USD
CY2020	vaso	Shares Withheld For Employee Tax Liability SharesWithheldForEmployeeTaxLiability	-4000	USD
CY2020	vaso	Reclassify Accumulated Translation Loss See Note N ReclassifyAccumulatedTranslationLossSeeNoteN	187000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	142000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	358000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	5085000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	5085000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	31000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	94000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	6100000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	11310000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	6100000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	358000	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3840000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2462000	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	52000	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-73000	USD
CY2021	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	73000	USD
CY2020	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-11000	USD
CY2021	vaso	Gainonforgivenessofppploan Gainonforgivenessofppploan	-3646000	USD
CY2020	vaso	Gain On Forgiveness Of Ppp Loan GainOnForgivenessOfPppLoan	0	USD
CY2021	us-gaap	Gain On Sale Of Investments GainOnSaleOfInvestments	0	USD
CY2020	us-gaap	Gain On Sale Of Investments GainOnSaleOfInvestments	110000	USD
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	448000	USD
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	663000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	31000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	88000	USD
CY2021	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-6052000	USD
CY2020	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	5050000	USD
CY2021	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	-46000	USD
CY2020	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	55000	USD
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	299000	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6000	USD
CY2021	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-1195000	USD
CY2020	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	407000	USD
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	162000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	193000	USD
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-212000	USD
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	350000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-3492000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-1369000	USD
CY2021	vaso	Increase Decrease In Accrued Commissions IncreaseDecreaseInAccruedCommissions	1497000	USD
CY2020	vaso	Increase Decrease In Accrued Commissions IncreaseDecreaseInAccruedCommissions	-859000	USD
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2372000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-265000	USD
CY2021	us-gaap	Increase Decrease In Property And Other Taxes Payable IncreaseDecreaseInPropertyAndOtherTaxesPayable	94000	USD
CY2020	us-gaap	Increase Decrease In Property And Other Taxes Payable IncreaseDecreaseInPropertyAndOtherTaxesPayable	-243000	USD
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	7260000	USD
CY2020	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-870000	USD
CY2021	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-233000	USD
CY2020	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	218000	USD
CY2021	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	78000	USD
CY2020	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-116000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	7815000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	5934000	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	415000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1000000	USD
CY2021	vaso	Paymentstoacquireinvestments Paymentstoacquireinvestments	-155000	USD
CY2020	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	725000	USD
CY2021	us-gaap	Proceeds From Divestiture Of Businesses And Interests In Affiliates ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates	0	USD
CY2020	us-gaap	Proceeds From Divestiture Of Businesses And Interests In Affiliates ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates	1150000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-260000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-575000	USD
CY2021	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	-5448000	USD
CY2020	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	-1375000	USD
CY2021	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
CY2020	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	3756000	USD
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	4000	USD
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	2881000	USD
CY2020	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1674000	USD
CY2021	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	USD
CY2020	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	1256000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-8329000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-553000	USD
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-20000	USD
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-111000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-794000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	4695000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6819000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2124000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6025000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6819000	USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	347000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	702000	USD
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	113000	USD
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	70000	USD
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	783000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	791000	USD
CY2021	vaso	Equipment Acquired Through Note Payable EquipmentAcquiredThroughNotePayable	0	USD
CY2020	vaso	Equipment Acquired Through Note Payable EquipmentAcquiredThroughNotePayable	42000	USD
CY2021	us-gaap	Nature Of Operations NatureOfOperations	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">NOTE A – DESCRIPTION OF BUSINESS</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Vaso Corporation was incorporated in Delaware in July 1987. For most of its history, the Company was a single-product company designing, manufacturing, marketing and servicing its proprietary Enhanced External Counterpulsation, or EECP<sup>®</sup>, therapy systems, mainly for the treatment of angina. In 2010 it began to diversify its business operations. The Company changed its name to Vaso Corporation in 2016 to more accurately reflect the diversified nature of its business mixture, and continues to use the original name VasoMedical for its proprietary medical device subsidiary. Unless the context requires otherwise, all references to “we”, “our”, “us”, “Company”, “registrant”, “Vaso” or “management” refer to Vaso Corporation and its subsidiaries. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Overview</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Vaso Corporation principally operates in three distinct business segments in the healthcare equipment and information technology industries. We manage and evaluate our operations, and report our financial results, through these three business segments.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">IT segment, operating through a wholly-owned subsidiary VasoTechnology, Inc., primarily focuses on healthcare IT and managed network technology services;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Professional sales service segment, operating through a wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare, primarily focuses on the sale of healthcare capital equipment for General Electric Healthcare (“GEHC”) into the health provider middle market; and</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Equipment segment, primarily focuses on the design, manufacture, sale and service of proprietary medical devices and software, operating through a wholly-owned subsidiary VasoMedical, Inc., which in turn operates through Vasomedical Solutions, Inc. for domestic business and Vasomedical Global Corp. for international business, respectively.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>VasoTechnology</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">VasoTechnology, Inc.<em> </em>was formed in May 2015, at the time the Company acquired all of the assets of NetWolves, LLC and its affiliates, including the membership interests in NetWolves Network Services, LLC (collectively, “NetWolves”). It currently consists of a managed network and security service division, NetWolves, and a healthcare IT application VAR (value added reseller) division, VasoHealthcare IT. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">In June 2014, the Company began its IT segment business by executing the Value Added Reseller Agreement (“VAR Agreement”) with GEHC to become a national value added reseller of GEHC Digital’s software solutions such as Picture Archiving and Communication System (“PACS”), Radiology Information System (“RIS”), and related services, including implementation, training, management and support. This business focuses primarily on customer segments currently served by VasoHealthcare on behalf of GEHC. A new wholly owned subsidiary, VasoHealthcare IT Corp. (“VHC IT”), was formed to conduct the healthcare IT business. The VAR Agreement with GEHC was terminated in 2021.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">In May 2015, the Company further expanded its IT segment business by acquiring NetWolves. NetWolves designs and delivers multi-network and multi-technology solutions as a managed network provider, and provides a complete single-source solution that includes design, network redundancy, application device management, real-time network monitoring, reporting and support systems as a comprehensive solution. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>VasoHealthcare</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">In May 2010, the Company launched its Professional Sales Service business through a wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare, which was appointed by GEHC as itsthe exclusive representative for the sale of select GEHC diagnostic imaging equipment to specific market segments in the 48 contiguous states of the United States and the District of Columbia. The original agreement (“GEHC Agreement”) has been extended several times and currently expires December 31, 2026, subject to earlier termination under certain conditions.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>VasoMedical</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The proprietary medical equipment business under VasoMedical traces back to 1995 when the Company began the proprietary Enhanced External Counterpulsation (EECP<sup>®</sup>) technology in the United States and has since diversified to include other medical hardware and software. Vasomedical Global was formed in 2011 to combine and coordinate the various international operations including design, development, manufacturing, and sales of medical devices and software, while domestic activities are conducted under Vasomedical Solutions. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Over the last decade the Company’s Equipment business has been significantly expanded from the original EECP<sup>®</sup>-only operations. In September 2011, the Company acquired Fast Growth Enterprises Limited (“FGE”), a British Virgin Islands company, which owned or controlled two Chinese operating companies - Life Enhancement Technology Ltd. (“LET”) based in Foshan, China, and Biox Instruments Co. Ltd. (“Biox”) based in Wuxi, China, respectively - to expand its technical and manufacturing capabilities and to enhance its distribution network, technology, and product portfolio. Biox was a variable interest entity (“VIE”) controlled by FGE through certain contracts and an option to acquire all the shares of Biox by FGE’s wholly owned subsidiary Gentone, and in March 2019 Gentone exercised its option to acquire all of the shares of Biox. In August 2014, the Company, through Gentone, acquired all of the outstanding shares of Genwell Instruments Co. Ltd. (“Genwell”), located in Wuxi, China. Genwell was formed in China in 2010 to develop the MobiCare<sup>®</sup> wireless multi-parameter patient monitoring system and holds intellectual property rights for this system. As a result, the Company has expanded its equipment products portfolio to include Biox™ series ambulatory patient monitoring systems, ARCS™ series software for ECG and blood pressure analysis, and the MobiCare<sup>®</sup> patient monitoring device. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">In April 2014, the Company entered into a cooperation agreement with Chongqing PSK-Health Sci-Tech Development Co., Ltd. (“PSK”) of Chongqing, China, the leading manufacturer of external counter pulsation, or ECP, therapy systems in China, to form a joint venture company, VSK Medical Limited (“VSK”), a Cayman Islands company, for the global marketing, sale and advancement of ECP therapy technology. The Company owned 49.9% of VSK, which commenced operations in January 2015. In March 2018, the Company terminated the cooperation agreement with PSK and sold its shares in VSK to PSK. On May 20, 2020, the Company closed on the sale of 51% of the capital stock of its wholly-owned subsidiary EECP Global Corporation (“EECP Global”) to PSK for $1,150,000. EECP Global was formed in September 2019 to hold all the assets and liabilities of its EECP business. Concurrently with the closing of the transaction, the Company signed a three-year Management Service Agreement with EECP Global to provide management service for the business and operation of EECP Global in the United States. Pursuant to the agreement, EECP Global reimburses the Company all direct expenses and pays a management fee starting April 1, 2020, the effective date of the sale.</p>
CY2015Q1	vaso	Company Ownership Rate CompanyOwnershipRate	0.499	pure
CY2020Q2	vaso	Capital Stock Sale To Subsidiaryrate CapitalStockSaleToSubsidiaryrate	0.51	pure
CY2020Q2	vaso	Capital Stock Sale To Subsidiary CapitalStockSaleToSubsidiary	1150000	USD
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates and assumptions relate to estimates of commissions adjustments due to order cancellations, collectability of accounts receivable, the realizability of deferred tax assets, stock-based compensation, values and lives assigned to acquired intangible assets, fair value of reporting units in connection with goodwill impairment test, the adequacy of inventory reserves, variable consideration, and allocation of contract transaction price to performance obligations. Actual results could differ from those estimates.</p>
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	75579000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	69850000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	75579000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	69850000	USD
CY2021	vaso	Transaction Price Allocated To Remaining Performance Obligations TransactionPriceAllocatedToRemainingPerformanceObligations	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">As of December 31, 2021, the aggregate amount of transaction price allocated to performance obligations that are unsatisfied (or partially unsatisfied) for executed contracts approximates $86 million, of which we expect to recognize revenue as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="14" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Fiscal years of revenue recognition</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">2024</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Thereafter</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Unfulfilled performance obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">49,308</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18,012</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,030</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12,659</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2021Q4	vaso	Revenue Remaining Performance Obligation Next Tewelve Year RevenueRemainingPerformanceObligationNextTewelveYear	49308	USD
CY2021Q4	vaso	Revenue Remaining Performance Obligation Second Year RevenueRemainingPerformanceObligationSecondYear	18012	USD
CY2021Q4	vaso	Revenue Remaining Performance Obligation Three Year RevenueRemainingPerformanceObligationThreeYear	6030	USD
CY2021Q4	vaso	Revenue Remaining Performance Obligation Thereafter RevenueRemainingPerformanceObligationThereafter	12659	USD
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	407000000	USD
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	553000000	USD
CY2020Q4	vaso	Contract With Customer Liability For Acceptances Of Equipment ContractWithCustomerLiabilityForAcceptancesOfEquipment	17689000000	USD
CY2021Q4	vaso	Contract With Customer Liability For Customer Order Reductions ContractWithCustomerLiabilityForCustomerOrderReductions	1518000000	USD
CY2020Q4	vaso	Contract With Customer Liability For Customer Order Reductions ContractWithCustomerLiabilityForCustomerOrderReductions	1118000000	USD
CY2021Q4	vaso	Contract With Customer Liability Post Delivery Services And Varying Duration Service ContractWithCustomerLiabilityPostDeliveryServicesAndVaryingDurationService	9000000	USD
CY2020Q4	vaso	Contract With Customer Liability Post Delivery Services And Varying Duration Service ContractWithCustomerLiabilityPostDeliveryServicesAndVaryingDurationService	15000000	USD
CY2021	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	5800000	USD
CY2021Q4	us-gaap	Deferred Sales Commission DeferredSalesCommission	5567000000	USD
CY2021Q4	vaso	Deferred Commission Expense DeferredCommissionExpense	3549000000	USD
CY2021Q4	vaso	Longterm Portion LongtermPortion	2018000000	USD
CY2021Q4	vaso	Consideration For Previously Completed Performance Obligations ConsiderationForPreviouslyCompletedPerformanceObligations	40000000	USD
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">We market our equipment and IT software solutions principally to hospitals, diagnostic imaging centers and physician private practices. We perform credit evaluations of our customers’ financial condition and, as a result, believe that our receivable credit risk exposure is limited. For the years ended December 31, 2021 and 2020, no customer in our equipment or IT segment accounted for 10% or more of revenues or accounts receivable. In our professional sales service segment, 100% of our revenues and accounts receivable are with GEHC; however, we believe this risk is acceptable based on GEHC’s financial position and our long history of doing business with GEHC. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The Company maintains cash balances in certain U.S. financial institutions, which, at times, may exceed the Federal Depository Insurance Corporation (“FDIC”) coverage of $250,000. The Company has not experienced any losses on these accounts and believes it is not subject to any significant credit risk on these accounts. In addition, the FDIC does not insure the Company’s foreign bank balances, which aggregated approximately $903,000 and $582,000 at December 31, 2021 and 2020, respectively.</p>
CY2021	us-gaap	Capitalized Computer Software Impairments1 CapitalizedComputerSoftwareImpairments1	1100000	USD
CY2021Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	0	USD
CY2020Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	541000000	USD
CY2021	us-gaap	Revenue Recognition Deferred Revenue RevenueRecognitionDeferredRevenue	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Amounts billable under the agreement with GEHC in advance of delivery of the underlying equipment are recorded initially as deferred revenue, and commission revenue is subsequently recognized as customer acceptance of such equipment is reported to us by GEHC. Similarly, commissions payable to our sales force related to such billings are recorded as deferred commission expense when the associated deferred revenue is recorded. Commission expense is recognized when the corresponding commission revenue is recognized.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">We record revenue on extended service contracts ratably over the term of the related service contracts. Under the provisions of ASC 606, we defer revenue related to EECP<sup>®</sup> system sales for the fair value of installation and in-service training to the period when the services are rendered and for service obligations ratably over the service period, which is generally one year. (See Note I)</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"> </p>
CY2021	vaso	Deferred Tax Asset Realized DeferredTaxAssetRealized	0.50	pure
CY2021	vaso	Customer Accountabilityfor Revenues Or Accounts Receivable CustomerAccountabilityforRevenuesOrAccountsReceivable	0.10	pure
CY2021	vaso	Revenues And Accounts Receivable Are With Gehc RevenuesAndAccountsReceivableAreWithGehc	1	pure
CY2021Q4	vaso	Fdic Coverage Exceed FdicCoverageExceed	250000000	USD
CY2021Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	903000000	USD
CY2020Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	582000000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	90000	shares
CY2021Q4	vaso	Restricted Common Stock Value RestrictedCommonStockValue	4500	USD
CY2021	vaso	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Valueofficers ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValueofficers	23000000	USD
CY2021	vaso	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Valueemployees ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValueemployees	14000000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.05
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	1000000	shares
CY2020Q4	vaso	Restricted Common Stock Value RestrictedCommonStockValue	20000	USD
CY2021	vaso	Shares Vested At Approximate Grant Date Rate SharesVestedAtApproximateGrantDateRate	0.20	pure
CY2021	vaso	Shares Vestedremaining SharesVestedremaining	0.80	pure
CY2020	vaso	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Valueofficers ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValueofficers	23000000	USD
CY2020	vaso	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Valueemployees ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValueemployees	63000000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.02
CY2021	us-gaap	Employee Benefits And Share Based Compensation Noncash EmployeeBenefitsAndShareBasedCompensationNoncash	31000	USD
CY2020	us-gaap	Employee Benefits And Share Based Compensation Noncash EmployeeBenefitsAndShareBasedCompensationNoncash	88000	USD
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	49000000	USD
CY2021Q4	vaso	Fair Value Cash Equivalents In Money Market Funds FairValueCashEquivalentsInMoneyMarketFunds	802	USD
CY2021Q4	vaso	Fair Value Bank Deposits In Short Term Investments FairValueBankDepositsInShortTermInvestments	629	USD
CY2021Q4	us-gaap	Fair Value Hedge Assets At Fair Value FairValueHedgeAssetsAtFairValue	1431	USD
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	4285000	USD
CY2021	vaso	Provision For Losses On Accounts Receivable ProvisionForLossesOnAccountsReceivable	132000	USD
CY2020	vaso	Provision For Losses On Accounts Receivable ProvisionForLossesOnAccountsReceivable	663000	USD
CY2021	vaso	Allowance For Doubtful Accounts Receivable Charge Offs Net Of Recoveries AllowanceForDoubtfulAccountsReceivableChargeOffsNetOfRecoveries	-77000	USD
CY2020	vaso	Allowance For Doubtful Accounts Receivable Charge Offs Net Of Recoveries AllowanceForDoubtfulAccountsReceivableChargeOffsNetOfRecoveries	-542000	USD
CY2021	vaso	Allowance For Doubtful Accounts Receivable Commission Adjustment AllowanceForDoubtfulAccountsReceivableCommissionAdjustment	1541000	USD
CY2020	vaso	Allowance For Doubtful Accounts Receivable Commission Adjustment AllowanceForDoubtfulAccountsReceivableCommissionAdjustment	-186000	USD
CY2021	vaso	Allowance For Doubtful Accounts Receivable Deconsolidation Adjustment AllowanceForDoubtfulAccountsReceivableDeconsolidationAdjustment	0	USD
CY2020	vaso	Allowance For Doubtful Accounts Receivable Deconsolidation Adjustment AllowanceForDoubtfulAccountsReceivableDeconsolidationAdjustment	-12000	USD
CY2021	vaso	Allowancefordoubtful Accountsandcommissionadjustmentsending AllowancefordoubtfulAccountsandcommissionadjustmentsending	5804	USD
CY2021	vaso	Longlived Assets To Be Impairedimpairments LonglivedAssetsToBeImpairedimpairments	324000000	USD
CY2021	us-gaap	Other Comprehensive Income Other Net Of Tax OtherComprehensiveIncomeOtherNetOfTax	94000000	USD
CY2020	us-gaap	Other Comprehensive Income Other Net Of Tax OtherComprehensiveIncomeOtherNetOfTax	142000000	USD
CY2020	vaso	Allowancefordoubtful Accountsandcommissionadjustmentsending AllowancefordoubtfulAccountsandcommissionadjustmentsending	4208	USD
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	171688	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	169932	shares
CY2021	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2083	shares
CY2020	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	914	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	173771	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	170846	shares
CY2021	us-gaap	Revenues Revenues	75579000	USD
CY2020	us-gaap	Revenues Revenues	69850000	USD
CY2021	us-gaap	Gross Profit GrossProfit	43133000	USD
CY2020	us-gaap	Gross Profit GrossProfit	38571000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	2819000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	772000	USD
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3840000	USD
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2462000	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	415000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1000000	USD
CY2021Q4	us-gaap	Assets Assets	52361000	USD
CY2020Q4	us-gaap	Assets Assets	50376000	USD
CY2020	us-gaap	Revenues Revenues	69850000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	21197000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	13960000	USD
CY2021Q4	us-gaap	Due From Employees Current DueFromEmployeesCurrent	0	USD
CY2020Q4	us-gaap	Due From Employees Current DueFromEmployeesCurrent	24000	USD
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	5804000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	4208000	USD
CY2021Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	15393000	USD
CY2020Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	9776000	USD
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	744000	USD
CY2020Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	669000	USD
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	4000	USD
CY2020Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	4000	USD
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	399000	USD
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	711000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	1147000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	1384000	USD
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	165000000	USD
CY2020Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	167000000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12684000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12718000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10512000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8833000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2172000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3885000	USD
CY2021	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	833000000	USD
CY2020	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	636000000	USD
CY2021	us-gaap	Depreciation Depreciation	1868000000	USD
CY2020	us-gaap	Depreciation Depreciation	1556000000	USD
CY2021Q4	us-gaap	Goodwill Fair Value Disclosure GoodwillFairValueDisclosure	14375000000	USD
CY2020Q4	us-gaap	Goodwill Fair Value Disclosure GoodwillFairValueDisclosure	1347000000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	15688000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	17271000	USD
CY2021	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	34000	USD
CY2021Q4	vaso	Trade Receivables Noncurrent TradeReceivablesNoncurrent	368000	USD
CY2020Q4	vaso	Trade Receivables Noncurrent TradeReceivablesNoncurrent	448000	USD
CY2020	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	82000	USD
CY2020	us-gaap	Goodwill Written Off Related To Sale Of Business Unit GoodwillWrittenOffRelatedToSaleOfBusinessUnit	1665000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	15722000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2041000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3949000	USD
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1972000000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	906000000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	560000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	339000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	270000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	186000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	144000	USD
CY2021Q4	vaso	Finite Lived Intangible Assets Amortization Expense FiniteLivedIntangibleAssetsAmortizationExpense	1499000	USD
CY2021Q4	vaso	Deferred Commission Expense Noncurrent DeferredCommissionExpenseNoncurrent	2018000	USD
CY2020Q4	vaso	Deferred Commission Expense Noncurrent DeferredCommissionExpenseNoncurrent	1683000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	60000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	59000	USD
CY2021	vaso	Effective Income Tax Rate EffectiveIncomeTaxRate	0.0242	pure
CY2020	vaso	Effective Income Tax Rate EffectiveIncomeTaxRate	-0.0028	pure
CY2021Q4	vaso	Income Tax Provision IncomeTaxProvision	151000	USD
CY2020Q4	us-gaap	Deferred Revenue DeferredRevenue	17704000	USD
CY2019Q4	us-gaap	Deferred Revenue DeferredRevenue	19343000	USD
CY2021	vaso	Deferred Revenue Deconsolidation DeferredRevenueDeconsolidation	0	USD
CY2020	vaso	Deferred Revenue Deconsolidation DeferredRevenueDeconsolidation	-769000	USD
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	16495000	USD
CY2020Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	11516000	USD
CY2021Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	8470000	USD
CY2020Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	6188000	USD
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	2397000	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	1331000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	1799000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	1854000	USD
CY2021Q4	us-gaap	Other Liabilities OtherLiabilities	3293000	USD
CY2020Q4	us-gaap	Other Liabilities OtherLiabilities	1969000	USD
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities AccountsPayableAndOtherAccruedLiabilities	7489000	USD
CY2020Q4	us-gaap	Accounts Payable And Other Accrued Liabilities AccountsPayableAndOtherAccruedLiabilities	5154000	USD
CY2021	us-gaap	Interest Costs Incurred InterestCostsIncurred	131000000	USD
CY2020	us-gaap	Interest Costs Incurred InterestCostsIncurred	287000000	USD
CY2015	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.09	pure
CY2021Q2	us-gaap	Repayments Of Debt RepaymentsOfDebt	1200000	USD
CY2021Q2	us-gaap	Debt Instrument Maturity Date Description DebtInstrumentMaturityDateDescription	The maturity date was extended again in March 2021 to June 30, 2022
CY2020Q2	us-gaap	Line Of Credit Facility Annual Principal Payment LineOfCreditFacilityAnnualPrincipalPayment	1200000	USD
CY2021	us-gaap	Legal Fees LegalFees	190000	USD
CY2020	us-gaap	Legal Fees LegalFees	227000	USD
CY2020Q4	us-gaap	Line Of Credit LineOfCredit	4346000	USD
CY2021Q4	us-gaap	Notes Payable NotesPayable	31000	USD
CY2020Q4	us-gaap	Notes Payable NotesPayable	3803000	USD
CY2020Q4	vaso	Notes Payable Medtech NotesPayableMedtech	3600000	USD
CY2021Q4	us-gaap	Debt And Capital Lease Obligations DebtAndCapitalLeaseObligations	31000	USD
CY2020Q4	us-gaap	Debt And Capital Lease Obligations DebtAndCapitalLeaseObligations	11749000	USD
CY2021Q4	us-gaap	Debt Current DebtCurrent	8000	USD
CY2020Q4	us-gaap	Debt Current DebtCurrent	5970000	USD
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	23000	USD
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	5779000	USD
CY2021Q4	vaso	Additional Principal Payment AdditionalPrincipalPayment	2000000.0	USD
CY2021Q1	us-gaap	Debt Instrument Periodic Payment Interest DebtInstrumentPeriodicPaymentInterest	675000000	USD
CY2020Q2	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0435	pure
CY2020Q2	vaso	Paycheck Protection Program Loan Amount PaycheckProtectionProgramLoanAmount	3610900000	USD
CY2020Q2	us-gaap	Debt Instrument Decrease Forgiveness DebtInstrumentDecreaseForgiveness	35000000	USD
CY2021	vaso	Lease Assets And Liabilities For Leases Term LeaseAssetsAndLiabilitiesForLeasesTerm	P12Y
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	222000	USD
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	190000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	562000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	540000	USD
CY2021Q4	vaso	Lease Liabilities Current LeaseLiabilitiesCurrent	784000	USD
CY2020Q4	vaso	Lease Liabilities Current LeaseLiabilitiesCurrent	730000	USD
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	218000	USD
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	246000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	352000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	469000	USD
CY2021Q4	vaso	Lease Liabilities Noncurrent LeaseLiabilitiesNoncurrent	570000	USD
CY2020Q4	vaso	Lease Liabilities Noncurrent LeaseLiabilitiesNoncurrent	715000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	265000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Rolling Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths	572000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	144000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Two LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo	232000	USD
CY2021Q4	vaso	Lease Liability Payments Due Year Two LeaseLiabilityPaymentsDueYearTwo	376000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	83000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Three LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree	114000	USD
CY2021Q4	vaso	Lease Liability Payments Due Year Three LeaseLiabilityPaymentsDueYearThree	197000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	26	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Four LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour	85	USD
CY2021Q4	vaso	Lease Liability Payments Due Year Four LeaseLiabilityPaymentsDueYearFour	111	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	518000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1003000	USD
CY2021Q4	vaso	Lease Liability Payments Due LeaseLiabilityPaymentsDue	1521000	USD
CY2021Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	78000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	89000	USD
CY2021Q4	vaso	Lease Liability Undiscounted Excess Amount LeaseLiabilityUndiscountedExcessAmount	-167000	USD
CY2021Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	440000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	914000	USD
CY2021Q4	vaso	Lease Liability LeaseLiability	1354000	USD
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	193000	USD
CY2020	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	198000	USD
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	45000	USD
CY2020	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	56000	USD
CY2021	vaso	Finance Lease Cost FinanceLeaseCost	238000	USD
CY2020	vaso	Finance Lease Cost FinanceLeaseCost	254000	USD
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	792000	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	712000	USD
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	78000	USD
CY2020	us-gaap	Short Term Lease Cost ShortTermLeaseCost	82000	USD
CY2021	us-gaap	Lease Cost LeaseCost	1108000	USD
CY2020	us-gaap	Lease Cost LeaseCost	1048000	USD
CY2021	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	45000	USD
CY2020	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	56000	USD
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	792000	USD
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	1799923	shares
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	712000	USD
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	199000	USD
CY2020	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	171000	USD
CY2021	vaso	Cash Paid For Amounts Included In Measurement Of Lease Liabilities CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities	1036000	USD
CY2020	vaso	Cash Paid For Amounts Included In Measurement Of Lease Liabilities CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities	939000	USD
CY2021Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.131	pure
CY2020Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.121	pure
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.088	pure
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.086	pure
CY2021	vaso	Withholding Taxrate WithholdingTaxrate	0.10	pure
CY2021	vaso	Reserves Reaches Rate ReservesReachesRate	0.50	pure
CY2021Q4	vaso	Statutory Reserves StatutoryReserves	35000000	USD
CY2021	vaso	Required After Profit Taxrate RequiredAfterProfitTaxrate	0.10	pure
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	11692020	shares
CY2019Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	5520208	shares
CY2019Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	0.03
CY2020	vaso	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Available For Future Issuance Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAvailableForFutureIssuanceGross	-1000000	shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1000000	shares
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	0.02
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-151000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.05
CY2020	vaso	Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Options Available For Future Issuance Forfeited Number Of Shares ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsAvailableForFutureIssuanceForfeitedNumberOfShares	328619	shares
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	328619	shares
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	0.10
CY2020	vaso	Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Options Available For Future Issuance Expired Number Of Shares ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOptionsAvailableForFutureIssuanceExpiredNumberOfShares	-15059	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	11005580	shares
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	4391666	shares
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	0.02
CY2021	vaso	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Available For Future Issuance Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAvailableForFutureIssuanceGross	-90000	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	90000	shares
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	0.05
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	1491666	shares
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	0.02
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	10915580	shares
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	2990000	shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.02
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	5720000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-74000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	531000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	431000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	6251000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	357000	USD
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	47000	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	78000	USD
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	52000	USD
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-7000	USD
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	99000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	71000	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	41000	USD
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	41000	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	11000	USD
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	11000	USD
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-124000	USD
CY2021	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	52000	USD
CY2020	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-72000	USD
CY2021	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	52000000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	47000	USD
CY2020	vaso	Due Primarily DuePrimarily	1000000	USD
CY2020	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	124000000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	47000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	454000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	125000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	110000	USD
CY2020	vaso	Partially Offset PartiallyOffset	78000000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0270	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.1939	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2132	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.0213	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.0084	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.6199	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	-0.0008	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.0139	pure
CY2021	vaso	Ppp Loan Forgiveness PPPLoanForgiveness	-0.1187	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.0006	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.0806	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.1277	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.1252	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0242	pure
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0028	pure
CY2021	vaso	Decrease Deferred Tax Assets DecreaseDeferredTaxAssets	1812000000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10769000	USD
CY2021	vaso	Deferred Tax Asset Valuation Allowancedecrease DeferredTaxAssetValuationAllowancedecrease	1376000000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	10015000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	12026000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	343000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	344000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	5000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	6000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	449000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	786000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	543000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	1330000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	1392000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	13105000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	14917000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10769000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	12145000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	2336000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	2772000	USD
CY2021Q4	vaso	Deferred Tax Liabilities Deferred Commissions DeferredTaxLiabilitiesDeferredCommissions	-325000	USD
CY2020Q4	vaso	Deferred Tax Liabilities Deferred Commissions DeferredTaxLiabilitiesDeferredCommissions	-370000	USD
CY2021Q4	us-gaap	Deferred Income Taxes And Other Assets Noncurrent DeferredIncomeTaxesAndOtherAssetsNoncurrent	219000	USD
CY2020Q4	us-gaap	Deferred Income Taxes And Other Assets Noncurrent DeferredIncomeTaxesAndOtherAssetsNoncurrent	271000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	219000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	271000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill	1703000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill	1445000	USD
CY2020	vaso	Licensing And Support Service LicensingAndSupportService	301000	USD
CY2021	vaso	Contingently Liable Letters Of Credit ContingentlyLiableLettersOfCredit	220500	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	89000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	686000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2117000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2501000	USD
CY2020Q4	us-gaap	Deferred Income Taxes And Other Liabilities Noncurrent DeferredIncomeTaxesAndOtherLiabilitiesNoncurrent	0	USD
CY2021Q4	us-gaap	Deferred Income Taxes And Other Liabilities Noncurrent DeferredIncomeTaxesAndOtherLiabilitiesNoncurrent	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	12145000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	12327000	USD
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-1376000	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-182000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10769000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	12145000	USD
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	31000000	USD
CY2021Q4	vaso	Net Operating Loss Carryforwards With No Expiration Date NetOperatingLossCarryforwardsWithNoExpirationDate	7000000	USD
CY2017Q4	vaso	Number Of States For Market Segments And Accounts NumberOfStatesForMarketSegmentsAndAccounts	48	integer
CY2019Q2	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	500000	USD
CY2021	vaso	Licensing And Support Service LicensingAndSupportService	343000	USD
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	129000	USD
CY2020	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	114000	USD

Files In Submission

Name	View Source	Status
0001654954-22-004333-index-headers.html	Edgar Link	pending
0001654954-22-004333-index.html	Edgar Link	pending
0001654954-22-004333.txt	Edgar Link	pending
0001654954-22-004333-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vaso-20211231.xsd	Edgar Link	pending
vaso-20211231_cal.xml	Edgar Link	unprocessable
vaso-20211231_def.xml	Edgar Link	unprocessable
vaso-20211231_lab.xml	Edgar Link	unprocessable
vaso-20211231_pre.xml	Edgar Link	unprocessable
vaso_10k.htm	Edgar Link	pending
vaso_10kimg1.jpg	Edgar Link	pending
vaso_10k_htm.xml	Edgar Link	completed
vaso_ex21.htm	Edgar Link	pending
vaso_ex311.htm	Edgar Link	pending
vaso_ex312.htm	Edgar Link	pending
vaso_ex321.htm	Edgar Link	pending
vaso_ex322.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VASO
VASO Corp Stock $vaso

2021 Form 10-K Financial Statement

#000165495422004333 Filed on March 31, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VASO VASO Corp Stock $vaso

2021 Form 10-K Financial Statement

#000165495422004333 Filed on March 31, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VASO
VASO Corp Stock $vaso